Feasibility of utilizing the 6-day subrenal capsule (SRC) assay to screen drugs against fresh surgical explants of human tumors was confirmed by testing six clinically active chemotherapeutic agents against 141 human breast cancers. Response rates of the six drugs obtained in the assay compared favorably with clinical response rates for the same drugs as reported by Carter (5). The evaluable assay rate for breast tumors was 92% as compared to 89% for gynecologic tumors. Innate drug resistance was indicated with 16 of 57 tumors (28~o) which did not respond to any of the six agents tested. Differences in responsiveness of tumors to each agent in a potential three-drug combination of either CMF or CAF suggest that the effectiveness of multiagent therapy might be enhanced if the individual agents of a potential drug combination were selected on the basis of tumor sensitivity to each of the agents in a predictive assay. Although cross-resistance between L-PAM and cytoxan was demonstrated and was statistically significant, 31 ~o of these tumors responded individually to either one or the other agent, suggesting cautionin extrapolating concomitance in activity between these two alkylators.
Introduction
The subrenal capsule (SRC) assay is a precise in vivo method for quickly determining the responsiveness of human tumor xenografts to chemotherapeutic agents, and was originally developed as an l 1-day assay for screening drugs against a panel of human tumors transplantable in the immunodeficient athymic nude mouse (1) . Its efficacy for evaluating drug activity has now been established, and the method has been incorporated into the Developmental Therapeutics Program of the Division of Cancer Treatment, National Cancer Institute, as a routine test system for evaluating drug activity against a panel of transplantation-established human tumors (2) .
Subsequent studies using both athymic nude and normal immunocompetent mice demonstrated that the SRC assay methodology was sensitive and precise enough to quantitate changes in xenograft size as early as three days post implantation (3) . Positive growth was demonstrable not only with human tumors that had been established in serial transplantation in athymic nude mouse hosts, but * Presented in part at the 4th Annual San Antonio Breast Cancer Symposium in November 1981 Address/or reprints." Dr. Arthur E. Bogden, Laboratory of Experimental Oncology, EG&G Mason Research Institute, Worcester MA also with primary surgical explants. These results suggested that the SRC assay methodology would permit use of the normal immunocompetent mouse in lieu of the athymic nude animal, simply by limiting the assay to six days to evade complications of an immune response.
Feasibility of utilizing human tumors as first transplant generation xenografts in the normal immunocompetent mouse for screening chemotherapeutic agents was demonstrated previously with 32 untreated human breast tumors in the 6-day SRC assay (4) . The present report updates the feasibility study with results obtained for 141 breast tumors, primarily from untreated patients. In addition, data relevant to the problem of drug resistance as detected by the SRC assay are presented and discussed.
Materials and methods
The SRC assay method as a rapid means to test drugs against human tumor xenografts has been published elsewhere (1) . In the 6-day SRC test model, preselected 1 mm cubed fragments of tumor tissue are implanted under the renal capsule of normal immunocompetent mice, a site ideal for delivery of nutrients and drugs. The tumor is easily visualized in situ and its size is measured across two diameters by using a stereoscopic microscope fitted with a micrometer calibrated in ocular micrometer units (omu) where 10 omu = 1.0 mm. There is no distortion of the implanted xenograft by surgical or histochemical fixation procedures. Since an initial and a final graft size is determined, oncolytic as well as growth inhibitory effects can be quantitated.
Five animals are implanted per test group and eight to ten in the control. Treatment is initiated the day following tumor implantation and continued on a QD 1-5 schedule. Drug doses are selected to be the maximally tolerated dose according to the schedule and route used in mice. Intravenous or subcutaneous routes are employed as appropriate for each drug. To avoid direct contact of the drug with the tumor, intraperitoneal injection is not used. Seven drugs, including standard as well as developmental agents, are tested routinely in an assay. The six standard, clinically active agents used in this study were L-phenylalanine mustard (L-PAM), cytoxan (CTX), methotrexate (MTX), 5-fluorouracil (5-FU), adriamycin (ADR), and vincristine (VCR).
The assay is terminated by sacrifice on day 6. Tumor-bearing kidneys are removed and final in situ tumor sizes determined. The parameter of drug activity is change in tumor size (ATS) that occurs over the 6-day test period. Thus, each xenograft provides its own baseline (initial size) for evaluating drug activity. A control value is not factored in to determine tumor response as in a percent test/control calculation. Assay data are reported as the average ATS values for the control and each of the experimental groups. In these studies, response to a drug was defined as an average ATS<-0.5 omu, which is equivalent to a regression in the calculated weight of the initial graft of > 13~. An assay was considered evaluable if tumor xenografts in untreated control mice remained stable in size (ATS 0.0 4-0.5 omu standard deviation) or grew over the 6-day period, i.e., provided a mean ATS>_-0.5 omu.
Results
The distribution of individual ATS values of 1184 untreated control xenografts, obtained from 141 human breast tumors tested in evaluable and unevaluable assays, is plotted in Fig. 1 . There is a distribution of individual ATS values on both sides of zero ATS, indicating that untreated human breast tumor xenografts, implanted under the renal capsule of normal immunocompetent mice for six days, can exhibit an increase or a decrease, as well as no measurable change in size. The type of distribution curve that was obtained would indicate that ATS is more a reflection of the individual xenograft than a non-specific host response to human tissue. Since necrotic and non-viable cellular elements are quickly cleared from the subcapsular site, regression of untreated xenografts reflects the quality of tissue selected for assay. That most untreated human breast tumor xenografts remained stable, i.e., produced no measurable change, or increased in size, is supported by the median ATS +0.5 omu, with at least 75~ of xenografts falling in the ATS range of -0.5 to +2.0 omu. Table 1 compares the percent distribution of untreated control xenograft ATS values (a) in all evaluable assays, i.e., assays of both drug responsive and unresponsive tumors, (b) in evaluable assays of tumors resistant to all drugs tested, and (c) in unevaluable assays, i.e., assays in which the mean control ~TS was < -0.5 omu. The percent distribution of ATS values of control xenografts from all evaluable assays and assays in which only drugresistant tumors were tested is remarkably similar. This suggests that innate drug resistance is not related to growth potential of the tumor, at least not as expressed by xenograft ATS. Clearly contrasted is the percent distribution of ATS values produced by xenografts in unevaluable assays. Although evaluable assays exhibit some variability in ATS of the individual xenografts, the criterion for unevaluability of a mean ATS<-0.5 omu effectively identifies those assays in which xenografts have an unacceptable decrease in size over the 6-day assay period. The evaluable assay rate of 92~ for breast tumors (Table 2 ) compares favorably with that of gynecologic tumors (89~). The ability of the SRC assay to detect clinically active agents is illustrated in Table 3 , showing the comparison of clinical experience with six drugs found to induce tumor regression in more than 20~o of breast cancer patients and the response rates of the same six drugs in the assay. The clinical response rates as reported by Carter (5) are based upon 3960 patients, and the SRC assay response rates on 130 breast tumors. Most of the patients in the clinical compilation had extensive therapy with endocrine maneuvers or other drugs prior to the single agent therapy, whereas over 9 3~ of the breast tumors tested in the assay were from previously untreated patients. This difference in patient p o p u l a t i o n m a y account for the somewhat higher response rates for L -P A M , CTX, and V C R in the assay. H a d these six drugs been developmental agents of u n k n o w n activity which were being tested for the first time against such a panel of r a n d o m l y selected h u m a n tumors, the results not only would have predicted their clinical activity, but also would have provided an indication of the relative potential of each drug for the specific treatment of breast cancer. This observation based on the results obtained with 130 breast tumors confirms our previous conclusion (4) made on the basis of 32 tumors.
Fifty-seven tumors were tested against all six chemotherapeutic agents. The number of tumors responding to each of the six drugs tested singly is summarized in Table 4 . Seventy-two percent of the tumors responded to at least one or more of the drugs. Of particular significance is that 28~o of the tumors were totally unresponsive.
Individuality of t u m o r sensitivity to chemotherapeutic agents can also be illustrated by examining the responses of breast tumors to each of the three agents used in clinically effective three-drug combinations for the treatment of breast cancer, C M F and C A F . Of 114 breast tumors treated with CTX, MTX, and 5-FU as single agents, only 17~ responded to all three (Table 5) ; of the 119 breast tumors treated with CTX, A D R , and 5-FU as single agents, only 12~o responded to all three ( Table 6 ). The most effective of the three drugs as a single agent was CTX, giving a response rate of 43~o. H a d C T X been administered to the same tumor p o p u l a t i o n as a three-drug C M F or C A F combination, the therapeutic response rates would Positive response = ATS < -0.5 omu. Positive response = ATS < -0 . 5 omu.
have been increased to 59~ and 56~, respectively (Tables 5 and 6 ).
Of particular importance are the 41% and 44% of the tumors that were responsive to only one or two drugs of a three-drug combination. From a treatment point of view, these results support the clinical effectiveness demonstrated with multi-agent therapy and the rationale for its use. However, these results also suggest that the effectiveness of such therapy might be enhanced if the individual agents of a potential drug combination were selected on the basis of a tumor's sensitivity to each of the agents in a predictive assay.
The SRC assay also permits examination of innate cross-resistance between drugs. Table 7 summarizes the responses of 107 human breast tumors to L-PAM and CTX as single agents. Significantly, 26% of the tumors were responsive and 43~o were unresponsive to both drugs, for an all-or-none response of 69%. However, 31% of the tumors responded to either L-PAM or CTX. Since over 93% of the tumors tested were from previously untreated patients, these data suggest caution in assuming concomitance in activity between these Positive response = ATS <-0.5 omu. Cross-resistance statistically significant at p = <0.001 level.
Positive response = •TS < -0.5 omu.
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Discussion
When used with fresh surgical explants, a mouse bearing a human tumor xenograft mimics the individual cancer patient. A 1 mm cubed fragment of tumor tissue implanted under the renal capsule approximates an organ micrometastasis, or the tumor burden remaining after reductive surgery.
Like the cancer in a human patient, each tumor xenograft provides its own initial tumor size measurement for evaluating chemotherapeutic activity. As in the clinic, drug activity in the SRC assay is indicated by the degree of regression or reduction in tumor size (-ATS) that has been induced by treatment. Evaluation of tumor response in the SRC assay is not determined by a numerical value calculated on the basis of an untreated control, such as is commonly used with experimental animal tumor systems, e.g., a % T/C (test value/control value) based on final tumor size or tumor weight. The control has been incorporated specifically to indicate the quality of the tumor tissue provided for assay.
No matter how carefully tissue is selected from a surgical or biopsy specimen for SRC assay, residual fibrous and cartilagenous elements as well as necrotic portions may be present in the tumor sample. These elements vary in type and quantity from specimen to specimen. Such heterogeneity in the ratios of malignant epithelium to stroma and necrosis is reflected in distribution of the ~TS values obtained with untreated control xenografts (Fig. 1) . As evident in Table 1 , assays meeting criteria for evaluability may have individual control xenografts showing some degree of regression. For this reason, several animals (8 to 10) are implanted with xenografts and left untreated as controls, and the mean ATS for the control group is utilized to indicate assay evaluability.
An observation made early in the development of the SRC assay which bears directly on the practicability of a 6-day assay time frame, is the apparent rapid clearance of necrotic tissue from the sub-capsular site. Thus, surgical specimens found histologically to be laced with extensive areas of necrosis, as well as tissues necrotized intentionally or due to mishandling, will be detected by extreme differences in ATS values of individual xenografts, or significant regression (resorption) of all xenografts resulting in a mean control ATS < -0.5 omu. Assays conducted with such tissues are easily flagged as being unevaluable.
Caution, however, is recommended in the interpretation of the drug resistant assay in which the tumor is unresponsive to all of the seven drugs tested but meets criteria for evaluability. Cartilagenous or fibrous tissue containing little or no malignant epithelium, more often found in primary breast tumor specimens than in metastases or in other gynecologic tumors, when implanted under the renal capsule for 6 days and left untreated, will produce little or no change in xenograft size, and the appearance of the xenograft resembles the tissue implanted. Such xenografts in treated animals will also be unresponsive to drug treatment, so that no significant drug effects in terms of graft regression will be evident. It is suggested, therefore, that the histopathology sections of such tumors might be reexamined to determine epithelial-stromal ratios. It is also recommended, as a monitoring and quality control procedure, that tissue submitted for assay be taken adjoining the sample selected for histopathology. Since tissues taken for a predictive test, like those taken for diagnostic histology, should be representative of the tumor mass, the importance of the pathologist in the selection of such tissues cannot be overemphasized.
This study has confirmed the feasibility of utilizing the 6-day SRC assay to screen drugs against fresh surgical explants of human tumors. As a drug screening test we have, arbitrarily, set the criterion for drug activity against breast tumor xenografts at a ATS <-0.5 omu to assure adequate sensitivity for the detection of new drugs. When applied as a clinical tool to predict individual tumor response, the criterion for drug activity (tumor response) has been set at a more stringent level of a ATS < -1.0 omu. Also, the difference between the mean ~TS values of the treated and control groups must be significant at the p<0.01 level. This statistical evaluation is applied only as a quality control measure to verify that the group mean values are not inordinately influenced by one or two xenografts, and represent acceptable uniformity in control growth and drug sensitivity.
